RxDoctor Payments Data

Karen Lane

Family · Fayetteville, GANPI 1336370360

Payments from drug & device makers

$2,486in general payments, 2019–2025

Across 140 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$487
  • Novo Nordisk$390
  • AbbVie$249
  • Pfizer$227
  • AstraZeneca$166
  • Novartis$155
  • plus $812 from 18 others

What the payments were for

  • Food & beverage$2,486100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,486 in reported general payments places this provider in the 80th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$35,233
Medicare patients
298
Services billed
602

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide18$21,206
EliquisApixaban17$13,732
XareltoRivaroxaban19$12,392
Sucralfate22$2,382
SynthroidLevothyroxine Sodium11$1,169
Nano 2nd Gen Pen NeedlePen Needle, Diabetic14$1,058
Atorvastatin Calcium125$1,022
Albuterol Sulfate HfaAlbuterol Sulfate25$835
Amlodipine Besylate137$737
Pantoprazole Sodium46$648
Omeprazole50$498
Tamsulosin Hcl28$466
Levothyroxine Sodium40$422
Fluticasone Propionate21$361
Gabapentin31$357

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$390$21,20618 claims
PfizerEliquis$227$13,73217 claims
Johnson & JohnsonXarelto$54$12,39219 claims
AbbVieSynthroid$249$1,16911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,258 family providers in Georgia.

Other family in Fayetteville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →